Emvododstat (PTC299) is an orally bioavailable small molecule that inhibits VEGF synthesis by binding the 5' and 3' untranslated regions of VEGF mRNA, preventing its translation. It is studied in pneumonia and COVID-19.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
PTC299
Drug type
Small molecule
Targets
VEGFA mRNA 5' and 3' untranslated regions (VEGFA)
Mechanism
Inhibitor of VEGFA mRNA 5' and 3' untranslated regions (VEGFA)
Pathways
angiogenesis, endothelial cell migration, proliferation and survival, tumor cell proliferation
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.